

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE  
HEALTH TECHNOLOGY APPRAISAL PROGRAMME  
Equality impact assessment – Guidance development  
STA**

**Spesolimab for treating generalised pustular psoriasis flares  
ID3963**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Consultation**

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
No
2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No
3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
The committee discussed a concern that had been raised about whether the use of the GPPGA pustulation subscore could potentially underestimate severity in people with darker skin as redness is less visible. The committee heard from clinical experts that assessment is based on the visibility of pustules and not the observation of redness therefore there was no cause for this concern. Clinical experts also confirmed that ethnicity is not a prognostic characteristic for General Pustular Psoriasis flares. The committee concluded that there are no other equality issues.
4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.
5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

Technology appraisals: Guidance development  
Equality impact assessment for the single technology appraisal Spesolimab for treating generalised pustular psoriasis flares [ID3963]

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Section 3.2.

**Approved by Associate Director (name):** Emily Crowe

**Date:** 16/01/2025

## Final draft guidance

(when draft guidance issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No potential equalities issues raised by stakeholders during consultation.

At the second meeting, the committee noted that the GPPGA total score, used in the definition of an initial flare, included an assessment of redness of skin. It agreed that healthcare professionals should take into account skin colour and how this could affect the GPPGA total score and make the necessary clinical adjustments. Clinical experts confirmed that ethnicity is not a prognostic characteristic.

The committee also noted that pregnancy can induce and exacerbate GPP in people with an existing predisposition. The company explained that there was no clinical evidence in people who had GPP in pregnancy, as these people were excluded from the Effisayil 1 trial. But the committee considered that its recommendation included people who develop moderate to severe GPP flares during and after pregnancy if healthcare practitioners consider spesolimab safe to use in these situations. The committee concluded that there are no other equality issues.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3.	If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	

  

4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No	

  

5.	Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes- section 3.26 of the final draft guidance.	

**Approved by Associate Director :** Emily Crowe.....

**Date:** 08/05/2025